Intrinsic subtypes and bladder cancer metastasis

David McConkey, Woonyoung Choi, Andrea Ochoa, Colin P.N. Dinney

Research output: Contribution to journalReview article

Abstract

Recent studies demonstrated that bladder cancers can be grouped into basal and luminal molecular subtypes that possess distinct biological and clinical characteristics. Basal bladder cancers express biomarkers characteristic of cancer stem cells and epithelial-to-mesenchymal transition (EMT). Patients with basal cancers tend have more advanced stage and metastatic disease at presentation. In preclinical models basal human orthotopic xenografts are also more metastatic than luminal xenografts are, and they metastasize via an EMT-dependent mechanism. However, preclinical and clinical data suggest that basal cancers are also more sensitive to neoadjuvant chemotherapy (NAC), such that most patients with basal cancers who are aggressively managed with NAC have excellent outcomes. Importantly, luminal bladder cancers can also progress to become invasive and metastatic, but they appear to do so via mechanisms that are much less dependent on EMT and may involve help from stromal cells, particularly cancer-associated fibroblasts (CAFs). Although patients with luminal cancers do not appear to derive much clinical benefit from NAC, the luminal tumors that are infiltrated with stromal cells appear to be sensitive to anti-PDL1 antibodies and possibly other immune checkpoint inhibitors. Therefore, neoadjuvant and/or adjuvant immunotherapy may be the most effective approach in treating patients with advanced or metastatic infiltrated luminal bladder cancers.

Original languageEnglish (US)
Pages (from-to)260-267
Number of pages8
JournalAsian Journal of Urology
Volume3
Issue number4
DOIs
StatePublished - Oct 1 2016

Fingerprint

Urinary Bladder Neoplasms
Epithelial-Mesenchymal Transition
Neoplasm Metastasis
Neoplasms
Stromal Cells
Heterografts
Drug Therapy
Neoplastic Stem Cells
Tumor Biomarkers
Immunotherapy
Anti-Idiotypic Antibodies

Keywords

  • Basal subtypes
  • Bladder cancer
  • Epithelial-to-mesenchymal transition
  • Luminal subtypes
  • Metastasis

ASJC Scopus subject areas

  • Urology

Cite this

Intrinsic subtypes and bladder cancer metastasis. / McConkey, David; Choi, Woonyoung; Ochoa, Andrea; Dinney, Colin P.N.

In: Asian Journal of Urology, Vol. 3, No. 4, 01.10.2016, p. 260-267.

Research output: Contribution to journalReview article

McConkey, David ; Choi, Woonyoung ; Ochoa, Andrea ; Dinney, Colin P.N. / Intrinsic subtypes and bladder cancer metastasis. In: Asian Journal of Urology. 2016 ; Vol. 3, No. 4. pp. 260-267.
@article{a336ad70d7ed4b8f83767867546e1989,
title = "Intrinsic subtypes and bladder cancer metastasis",
abstract = "Recent studies demonstrated that bladder cancers can be grouped into basal and luminal molecular subtypes that possess distinct biological and clinical characteristics. Basal bladder cancers express biomarkers characteristic of cancer stem cells and epithelial-to-mesenchymal transition (EMT). Patients with basal cancers tend have more advanced stage and metastatic disease at presentation. In preclinical models basal human orthotopic xenografts are also more metastatic than luminal xenografts are, and they metastasize via an EMT-dependent mechanism. However, preclinical and clinical data suggest that basal cancers are also more sensitive to neoadjuvant chemotherapy (NAC), such that most patients with basal cancers who are aggressively managed with NAC have excellent outcomes. Importantly, luminal bladder cancers can also progress to become invasive and metastatic, but they appear to do so via mechanisms that are much less dependent on EMT and may involve help from stromal cells, particularly cancer-associated fibroblasts (CAFs). Although patients with luminal cancers do not appear to derive much clinical benefit from NAC, the luminal tumors that are infiltrated with stromal cells appear to be sensitive to anti-PDL1 antibodies and possibly other immune checkpoint inhibitors. Therefore, neoadjuvant and/or adjuvant immunotherapy may be the most effective approach in treating patients with advanced or metastatic infiltrated luminal bladder cancers.",
keywords = "Basal subtypes, Bladder cancer, Epithelial-to-mesenchymal transition, Luminal subtypes, Metastasis",
author = "David McConkey and Woonyoung Choi and Andrea Ochoa and Dinney, {Colin P.N.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.ajur.2016.09.009",
language = "English (US)",
volume = "3",
pages = "260--267",
journal = "Asian Journal of Urology",
issn = "2214-3882",
publisher = "Elsevier (Singapore) Pte Ltd",
number = "4",

}

TY - JOUR

T1 - Intrinsic subtypes and bladder cancer metastasis

AU - McConkey, David

AU - Choi, Woonyoung

AU - Ochoa, Andrea

AU - Dinney, Colin P.N.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Recent studies demonstrated that bladder cancers can be grouped into basal and luminal molecular subtypes that possess distinct biological and clinical characteristics. Basal bladder cancers express biomarkers characteristic of cancer stem cells and epithelial-to-mesenchymal transition (EMT). Patients with basal cancers tend have more advanced stage and metastatic disease at presentation. In preclinical models basal human orthotopic xenografts are also more metastatic than luminal xenografts are, and they metastasize via an EMT-dependent mechanism. However, preclinical and clinical data suggest that basal cancers are also more sensitive to neoadjuvant chemotherapy (NAC), such that most patients with basal cancers who are aggressively managed with NAC have excellent outcomes. Importantly, luminal bladder cancers can also progress to become invasive and metastatic, but they appear to do so via mechanisms that are much less dependent on EMT and may involve help from stromal cells, particularly cancer-associated fibroblasts (CAFs). Although patients with luminal cancers do not appear to derive much clinical benefit from NAC, the luminal tumors that are infiltrated with stromal cells appear to be sensitive to anti-PDL1 antibodies and possibly other immune checkpoint inhibitors. Therefore, neoadjuvant and/or adjuvant immunotherapy may be the most effective approach in treating patients with advanced or metastatic infiltrated luminal bladder cancers.

AB - Recent studies demonstrated that bladder cancers can be grouped into basal and luminal molecular subtypes that possess distinct biological and clinical characteristics. Basal bladder cancers express biomarkers characteristic of cancer stem cells and epithelial-to-mesenchymal transition (EMT). Patients with basal cancers tend have more advanced stage and metastatic disease at presentation. In preclinical models basal human orthotopic xenografts are also more metastatic than luminal xenografts are, and they metastasize via an EMT-dependent mechanism. However, preclinical and clinical data suggest that basal cancers are also more sensitive to neoadjuvant chemotherapy (NAC), such that most patients with basal cancers who are aggressively managed with NAC have excellent outcomes. Importantly, luminal bladder cancers can also progress to become invasive and metastatic, but they appear to do so via mechanisms that are much less dependent on EMT and may involve help from stromal cells, particularly cancer-associated fibroblasts (CAFs). Although patients with luminal cancers do not appear to derive much clinical benefit from NAC, the luminal tumors that are infiltrated with stromal cells appear to be sensitive to anti-PDL1 antibodies and possibly other immune checkpoint inhibitors. Therefore, neoadjuvant and/or adjuvant immunotherapy may be the most effective approach in treating patients with advanced or metastatic infiltrated luminal bladder cancers.

KW - Basal subtypes

KW - Bladder cancer

KW - Epithelial-to-mesenchymal transition

KW - Luminal subtypes

KW - Metastasis

UR - http://www.scopus.com/inward/record.url?scp=85027892013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027892013&partnerID=8YFLogxK

U2 - 10.1016/j.ajur.2016.09.009

DO - 10.1016/j.ajur.2016.09.009

M3 - Review article

AN - SCOPUS:85027892013

VL - 3

SP - 260

EP - 267

JO - Asian Journal of Urology

JF - Asian Journal of Urology

SN - 2214-3882

IS - 4

ER -